Clinical trial
Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient…
NCT00411281 · Children's Oncology Group, Other · Withdrawn
Key facts
| NCT number | NCT00411281 |
|---|---|
| Title | Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder |
| Official title | Treatment of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS) |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug, Procedure |
| Interventions | cytarabine, observation |
| Enrollment | 0 |
| Start date | Mar 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Dec 13, 2006 |
| Last update posted | Sep 30, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: